Mel Walker

When NHS resources are stretched to the limit, time and cost saving opportunities can help funnel resources back into patient care - get in contact and find out how iethico can help community & hosptial pharmacy and dispensing doctors save time resource and costs iethico

5

Thank you for organizing the masterclass Barts Life Sciences 🙏🏼 —it was an insightful event with excellent networking opportunities. Here are 3 key tips for SMEs/startups aiming to penetrate the NHS, which I gathered from the event: 1. Align with the Integrated Care Strategy (ICS) to scale your solution effectively within the NHS and align with Trust priorities. 2. Determine in advance which care setting (primary, secondary, or tertiary) your solution best fits. 3. Emphasize Patient and Public Involvement Engagement (PPIE). Ensuring patients and the public are central to your solution is crucial for scaling. I also found it fascinating to learn about specific business cases, how they are assessed internally by the Trust, and understanding the decision-making process and timescale. Barts Health NHS Trust Kadans Science Partner Queen Mary University of London Canary Wharf Group 🙏🏼

2

Excited to see Rachael M.,Philip W. and Alex Miller's insights on the #DigitalHealth space in Europe with the launch of Wavestone’s first Digital Health Radar, available here: https://lnkd.in/gRXuF2t5   The Radar gives an overview of the investment landscape of digital health startups in Europe, providing food for thought on some emerging market characteristics, including the importance of: -The right information -Patient-centered care -End-to-end patient journey -Evidence-based solutions   Take a look and find out more. #DigitalHealth #Healthtech #Innovation #Investment #Startup

7

1 Comment

In Autumn last year #kpmglifesciences convened a round table with Amit Aggarwal to discuss Factors affecting innovative prescribing in the UK and the role of the clinician in improving access to innovative medicines. Despite NICE approving innovative medicines, uptake varies across England, leading to unequal health outcomes. This article explores barriers to uptake and the role clinicians play in improving accessibility. Key points: 💡 Clinicians' attitudes towards newer medicines vary, with some displaying skepticism or caution. This may be due to limited information, perceived hype, or a general "safety-first" approach in the UK. 💡 The UK's generalist GP role and high proportion of non-medical prescribers may also contribute to conservatism. 💡 However, there are pockets of innovation, especially where significant care gaps exist and industry partners with the NHS. 💡 The new Integrated Care Systems (ICSs) model may encourage innovation by emphasizing preventative treatment and aligning primary and secondary care. This highlights the need for further investigation into cultural factors and professional boundaries impacting innovation adoption. Stay tuned for the outputs of the follow-up event held in February. If you would like to be invited to future events, please comment below #kpmglifesciences #innovation #healthcare #medicines #access #clinicians #ICSs Guillaume Favier, Helena Szpytman, Adrian Griffiths

45

3 Comments

Dear Market Access Leaders, Imagine you're on the cusp of launching a ground-breaking drug —a product that could transform patient outcomes and revolutionise treatment paradigms. Your team has meticulously crafted value propositions. Honed messages.  And prepared robust evidence for Health Technology Assessment (HTA) submissions. But here's the catch . . . What if I told you that despite your best efforts, a crucial ingredient that could make or break your market access strategy is slipping through the cracks — left untapped and unused? As Market Access Leaders, we pride ourselves on our strategic skills and our ability to navigate the complexities of HTA processes. Yet, in our mission to secure reimbursement and market access, we often overlook this fundamental ingredient that could make Reimbursement & Access quicker — faster — and easier. 🙋🏼‍♀️❓❓❓ Question: Can you guess what the missing ingredient is? Please share your answers in the comments below. 👇 👇👇 #MarketAccess #CustomerInsights #Payers #HTA #MarketResearch

10

6 Comments

The medicines and vaccines our industry develops are transformative for public health, patients and the NHS and our industry’s success depends on strong partnerships between industry and government.   Together, we can achieve better health and economic growth find out how: https://lnkd.in/eXcG2RrF   #ABPImanifesto

49

In this statement, the EFPIA shares its concerns with the proposed implementation of joint clinical assessments in the EU. It seems further work is needed on improving the transparency, predictability and workability for companies. 📉🏛️ Perhaps greater collaboration would reduce the uncertainty around JCA implementation. One idea articulated in this statement is a fairly simple ask - initiating scoping meetings, as is done in many countries, which would assist in the early exchange of information between the industry and the assessors. 🤝🌍 Have a look at the post for further details. 🔍📄 #EFPIA #HTA #HealthcarePolicy https://lnkd.in/d4_dZ-KR

4

More exciting news on GLP-1 agonists: At a time when you think the excitement could not be any higher, we hear even more promising news about clinical use of GLP-1 agonists.  “The Times” published an article this morning (May 14) with these key messages: 1. Millions of middle-aged Britons should be routinely prescribed weight-loss injections to cut their risk of heart attacks and strokes by a fifth, according to a trial set to revolutionise medical practice. 2. The largest study ever into semaglutide, also known as Ozempic or Wegovy, found the drug cuts heart disease deaths by about 20 per cent even if people don’t lose weight. 3. The results — presented at the European Congress on Obesity in Venice — were hailed as the biggest medical breakthrough since the introduction of statins in the 1990s. A link to the publication in Nature Medicine and a link to the clinical study named SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity) is attached below. Key findings are as follows: 1. The trial involved 17,604 adults over the age of 45 who had heart disease — a condition that affects 7.6 million in the UK — or had had a heart attack or stroke. All were overweight or obese, but none had diabetes. Half were given weekly semaglutide injections and the rest a placebo.  2. Over a trial period of three years and four months, the group who took semaglutide had a 20 per cent lower risk of heart attack, stroke or death from heart disease and also lost nine per cent of their body weight on average. 3. The drug delivered heart benefits regardless of how much weight people lost. Times articles: https://lnkd.in/gwHVj3P6 https://lnkd.in/gSk-HQTV Clinical results: https://lnkd.in/gvAmaBY8 https://lnkd.in/gAJEWPZF News: https://lnkd.in/gyDZ8wGN https://lnkd.in/gF_UK9W8 https://lnkd.in/gximb9S6 https://lnkd.in/gfqvZFd9 https://lnkd.in/g-pDYRJp

64

2 Comments

Interesting to see the various hybrid working models deployed in the healthcare and life science industry and how this will continue to evolve with the help of technology. GSK is certainly one of many life science companies leading the way toward more efficient and collaborative work spaces, but proving once again that office isn't going away, the demand and utilization is of this asset class is just changing to be more efficient and amenitized.

11

Excellent news and good to see the IMF finally being used as was originally intended. Perhaps this breakthrough deal with CSL Behring's Hemgenix (haemophilia B) will now give industry more confidence and an 'art-of-the-possible' mindset in order to create more managed access for promising new non-cancer medicines. #access #health and access to medicines # pricing # value # IMF # NICE # NHS commercial framework for new medicines

11

What were the key findings of the State of Market Access 2024 Survey? What are some untapped opportunities? What do the payers say?   Get your copy to find out more. #marketaccess #stateofmarketaccess

5

🎙️ In a recent episode of Diary of a CEO, Steven Bartlett shared a thought-provoking perspective on entrepreneurship. Contrary to popular belief, entrepreneurs don't just escape the traditional boss; they actually end up with many bosses! That’s TRUE! This turns the idea of the 'boss-free' lifestyle on its head, highlighting that entrepreneurship is not about losing your boss, but about choosing your bosses. #Entrepreneurship #Leadership #BusinessInsights #StevenBartlett Full episode: https://lnkd.in/eZkk6S8k

11

Thoughts on this? >> Four key takeaways for biopharma from Labour’s win in the UK election >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #pharma #productmarketing #healthcare

1

A great example of a patient organisation with a clear vision and data strategy representing and speaking loud and clear on behalf of their members! Patient organisations play a crucial role in driving research and care transformation, helping to shape healthcare systems with healthier communities. Unlocking the power of NHS patient data has the potential to transform healthcare and research in the UK. With responsible and effective use of data, we can improve health, make the NHS more efficient, and solidify the UK's status as a global innovator. In collaboration with patients, academia, industry and the charity sector we can do great things to unlock patient data to transform research taking in consideration: ➡ Importance of Public Confidence: A key element is engaging the public and healthcare professionals to build trust ➡ Data Quality and Access: Address the challenges related to data quality, fragmented datasets, and slow processes for data access ➡ Governance and Standards: Focus on the need for a clear framework with consistent governance and standards to facilitate access to data ➡ Research Integration within NHS: Research within the NHS to improve care is crucial ➡ Disease-Specific Research:  Consider patient data to drive impactful research and improve patient outcomes. Thank you Association of Medical Research Charities for the clear and challenging vision #healthcareinnovation #PatientData #ResearchTransformation #Advocacy #Patientadvocacy

5

2 Comments

In the UK, the Pharmacy First concept is being further expanded. The aim is to give even greater priority to self-care when it comes to minor health problems. NHS estimates that this could save around 10 million visits to the doctor each year. People on low incomes will even be able to buy OTC medicines at pharmacies free of charge. In the light of the figures that May und Bauer has calculated for the AESGP, the British ideas are only logical: according to our calculations, for every euro spent on OTC medicines, almost seven Euros are saved for the health care system and economies. Therefore, it makes sense to invest money in promoting self-care in order to save social resources. https://lnkd.in/esiXqvaN

39

3 Comments

In the UK, life sciences represent the top-spending private R&D sector, driving medical progress and bringing new treatments to patients that can transform their quality of life.   Creating a seamless life sciences ecosystem is key to rapid approvals and adoption of new medicines and use by the NHS.   Let's make the UK a hub for innovation: https://lnkd.in/eXcG2RrF   #ABPImanifesto

2

World Asthma Day marks an important opportunity to acknowledge the urgent unmet need in severe asthma, a distinct and frequently underestimated condition presenting unique challenges to quality of life.    Patients often face a long and difficult journey from diagnosis to management. AstraZeneca is calling for policy reform, which supports severe asthma patients and addresses some of the barriers they currently face moving from primary through to secondary care. Watch the full video and find out more! #WorldAsthmaDay

23